Home › Journal › No. 2168 › Class 99 › Priority claimed from 04/05/2021; Application No. : 90689670 ;United States of America

Priority claimed from 04/05/2021; Application No. : 90689670 ;United States of America · application 5199384, class 99

Advertised in Trade Marks Journal No. 2168 on 5 August 2024. Opposition window closes 5 December 2024.

Priority claimed from 04/05/2021; Application No. : 90689670 ;United States of America

Application
5199384 · filed 3 November 2021 · Delhi office
Class
Class 99:
Applicant
Lyell Immunopharma, Inc. (Company, foreign)
Use claimed
Proposed to be used
Advertised
Trade Marks Journal No. 2168, 5 August 2024

Is Priority claimed from 04/05/2021; Application No. : 90689670 ;United States of America trademarked? Every application under this name →

Goods or services claimed

Cl.5;Pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, and infectious diseases; cells for medical or clinical purposes; pharmaceutical preparations for cell therapy for medical or clinical purposes; pharmaceutical preparations for gene therapy for medical or clinical purposes; kits comprised of cells and pharmaceutical preparations for medical or clinical purposes Cl.40;Manufacturing services Cl.42;Pharmaceutical research and development; development of pharmaceutical preparations and drugs; development of pharmaceutical preparations and drugs for the treatment of cancer, auto-immune diseases, and infectious diseases; development of pharmaceutical preparations and drugs in the field of immunotherapy; development of pharmaceutical preparations and drugs in the field of cell therapy; scientific research and development; scientific laboratory services; medical and scientific research; scientific and technological services and biological research and development relating thereto, namely, research and development utilizing integrated technology platforms combining chemical, molecular, genetic, protein and cell systems engineering technologies for therapeutic regulation of cells and cell systems, namely, therapeutic regulation of immune cells; scientific and technological services and biological research and development, namely, research and development related to treatment of cancer Cl.44;Medical services; medical services, namely, medical se

Opposition window closes 5 December 2024. This mark has passed examination and is advertised so that anyone with an earlier right can object. A notice of opposition (Form TM-O) may be filed until that date; after it, the application proceeds to registration and the mark can only be challenged by rectification. Whether an opposition is worth filing depends on how close the marks are and whether the goods overlap: see how opposition works.

Similar marks in class 99, same issue

Found by the same matcher that powers Brand Watch: identical, contained, near-spellings and sounds-alike names.

What "advertised" means for Priority claimed from 04/05/2021; Application No. : 90689670 ;United States of America

Advertised is not registered. The Registry examined the application, found no bar (or the applicant overcame the objection), and published it. Registration follows only if no opposition is filed within four months, or if an opposition fails. Until the certificate issues, the applicant may use ™ but not ®. Our guide to trademark status meanings explains each stage, and how long registration takes gives realistic timelines.

Source and corrections. Details are reproduced as advertised by the Registrar of Trade Marks in the Trade Marks Journal (a public record) and may contain errors of transcription. Applicants may ask for a correction or removal of their entry by writing to mehak@trademarkindia.pro. This page is information, not legal advice and not a solicitation.

WhatsApp us